JP2014517694A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517694A5
JP2014517694A5 JP2014512189A JP2014512189A JP2014517694A5 JP 2014517694 A5 JP2014517694 A5 JP 2014517694A5 JP 2014512189 A JP2014512189 A JP 2014512189A JP 2014512189 A JP2014512189 A JP 2014512189A JP 2014517694 A5 JP2014517694 A5 JP 2014517694A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
nucleic acid
acid sequence
vector
viral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014512189A
Other languages
English (en)
Japanese (ja)
Other versions
JP6162104B2 (ja
JP2014517694A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/039897 external-priority patent/WO2012162705A2/en
Publication of JP2014517694A publication Critical patent/JP2014517694A/ja
Publication of JP2014517694A5 publication Critical patent/JP2014517694A5/ja
Application granted granted Critical
Publication of JP6162104B2 publication Critical patent/JP6162104B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014512189A 2011-05-26 2012-05-29 細胞及び遺伝子に基づく心臓機能改善方法 Active JP6162104B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490450P 2011-05-26 2011-05-26
US61/490,450 2011-05-26
PCT/US2012/039897 WO2012162705A2 (en) 2011-05-26 2012-05-29 Cell and gene based methods to improve cardiac function

Publications (3)

Publication Number Publication Date
JP2014517694A JP2014517694A (ja) 2014-07-24
JP2014517694A5 true JP2014517694A5 (enExample) 2015-07-16
JP6162104B2 JP6162104B2 (ja) 2017-07-12

Family

ID=47218136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014512189A Active JP6162104B2 (ja) 2011-05-26 2012-05-29 細胞及び遺伝子に基づく心臓機能改善方法

Country Status (10)

Country Link
US (1) US9868937B2 (enExample)
EP (1) EP2714709B1 (enExample)
JP (1) JP6162104B2 (enExample)
KR (1) KR20140035967A (enExample)
CN (1) CN103946230B (enExample)
AU (1) AU2012258525B2 (enExample)
BR (1) BR112013030209A2 (enExample)
CA (1) CA2837322C (enExample)
RU (1) RU2608957C2 (enExample)
WO (1) WO2012162705A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140035967A (ko) 2011-05-26 2014-03-24 유니버시티 오브 워싱톤 세포 및 유전자에 기반한 심장 기능을 개선하는 방법
EP2792742A1 (en) * 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
WO2015153357A1 (en) * 2014-03-29 2015-10-08 Beat Biotherapeutics Corp. Compositions and methods for improving cardiac function
AU2016206518B2 (en) * 2015-01-16 2020-03-05 University Of Washington Novel micro-dystrophins and related methods of use
EP3719134B1 (en) 2015-03-11 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Rp2 vectors for treating x-linked retinitis pigmentosa
US10118034B2 (en) * 2015-08-18 2018-11-06 Boston Scientific Scimed, Inc. Methods for producing cardiomyocyte cells
CA3089957C (en) 2017-02-04 2024-01-23 AnaBios Corporation System and methods for predicting drug-induced inotropic and pro-arrhythmia risk
CN108913655B (zh) * 2018-07-16 2022-07-15 浙江大学 基于多能干细胞技术建立“人源性”心肌肥大模型的方法
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
AU2019333315B2 (en) 2018-08-30 2022-09-29 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with myocardin and ASCL1
US20200405824A1 (en) * 2019-06-26 2020-12-31 University Of Washington Use of ribonucleotide reductase alone or in combination with micro-dystrophin to treat duchenne muscular dystrophy striated muscle disease
CN110384800B (zh) * 2019-07-19 2021-06-08 广东省实验动物监测所 LncRNA XLOC_075168在制备促进血管新生的药物中的应用
MY209860A (en) 2020-02-13 2025-08-07 Tenaya Therapeutics Inc Gene therapy vectors for treating heart disease
EP4319775A4 (en) * 2021-04-06 2025-03-05 University of Washington NON-CONTRACTILE CARDIOMYOCYTES FOR HEART REPAIR
CN120758566B (zh) * 2025-09-10 2025-11-21 瓯江实验室 一种在心肌细胞中特异性过表达zer1的病毒载体的构建及在心衰治疗中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02240440A (ja) 1989-03-14 1990-09-25 Shiigeru:Kk 慣性ダンパ
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US6151525A (en) 1997-11-07 2000-11-21 Medtronic, Inc. Method and system for myocardial identifier repair
WO1999062940A2 (en) * 1998-05-30 1999-12-09 Collateral Therapeutics, Inc. Methods of altering cardiac cell phenotype
US6451594B1 (en) * 1998-09-11 2002-09-17 The Regents Of The University Of California Recombinant adenovirus for tissue specific expression in heart
CA2356551A1 (en) * 1998-12-28 2000-07-06 Arch Development Corporation Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
WO2002049714A2 (en) * 2000-12-21 2002-06-27 Medtronic, Inc. Electrically responsive promoter system
WO2003094697A2 (en) * 2002-05-08 2003-11-20 The Regents Of The University Of California Methods and compositions for correction of cardiac conduction disturbances
WO2004024867A2 (en) * 2002-09-11 2004-03-25 University Of Florida Vigilant vector system
CA2535680A1 (en) * 2003-08-11 2005-02-24 University Of South Florida Vigilant cells
ATE532863T1 (de) * 2003-11-21 2011-11-15 Daiichi Sankyo Co Ltd Verfahren zur anzucht von myokardzellen
US20050260637A1 (en) * 2004-03-25 2005-11-24 Yun Yen Drug screening
DE102011018586A1 (de) * 2011-04-26 2012-10-31 Oliver Müller Vektorsystem zur spezifischen Genexpression im Herzmuskel
KR20140035967A (ko) 2011-05-26 2014-03-24 유니버시티 오브 워싱톤 세포 및 유전자에 기반한 심장 기능을 개선하는 방법

Similar Documents

Publication Publication Date Title
JP2014517694A5 (enExample)
CL2019002280A1 (es) Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235)
JP2019513393A5 (enExample)
PH12020550094A1 (en) Adeno-associated virus variant capsids and methods of use thereof
AR129651A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
JP2017538401A5 (enExample)
PH12020551744A1 (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
JP2019513399A5 (enExample)
RU2016123086A (ru) Способы и композиции для лечения болезни хантингтона
JP2014512171A5 (enExample)
EA201991911A1 (ru) Способы и композиции для переноса генов по сосудистой сети
JP2018520997A5 (enExample)
WO2015158749A3 (de) Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark
EP4407035A3 (en) Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy
JP2017048194A5 (enExample)
HRP20250541T1 (hr) Isporuka mikro-distrofina s adeno-povezanim virusnim vektorom za liječenje mišićne distrofije
MX2014009975A (es) Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos.
MX2020010464A (es) Vectores de virus que evitan anticuerpos.
PE20150163A1 (es) Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav
EA201492048A1 (ru) Полипептиды, связывающиеся с хемокиновым рецептором
JP2013501816A5 (enExample)
FI3581650T3 (fi) IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
JP2019523648A5 (enExample)
JP2018531624A5 (enExample)